|
| Press Releases |
|
 |
|
| Friday, May 27, 2022 |
|
|
Eisai Contributes to the Science of Cancer Medicine at ASCO 2022 |
| Eisai Co., Ltd. announced today the presentation of research across various types of cancer from its oncology portfolio during the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting (#ASCO22), which is taking place virtually and in-person in Chicago from June 3 to 7. more info >> |
|
|
Eisai: MHLW Grants Orphan Drug Designation in Japan to Mecobalamin Ultrahigh-Dose Formulation with Prospective Indication for Delaying the Progression of Disease and Functional Impairment of ALS |
| Eisai Co., Ltd. announced today that it has received orphan drug designation for ultrahigh-dose mecobalamin, with a prospective indication for delaying the progression of disease and functional impairment of amyotrophic lateral sclerosis (ALS), by the Ministry of Health, Labour and Welfare (MHLW). more info >> |
|
| Tuesday, May 10, 2022 |
|
|
Eisai Completes Rolling Submission to the U.S. FDA for Biologics License Application of Lecanemab for Early Alzheimer's Disease Under the Accelerated Approval Pathway |
| Eisai Co., Ltd. and Biogen Inc. announced today that Eisai has completed the rolling submission to the U.S. Food and Drug Administration (FDA) of a Biologics License Application (BLA) under the accelerated approval pathway. more info >> |
|
|
Eisai Initiates Preparation for New Drug Application, Based on the Results of an Investigator-Initiated Clinical Trial of Ultrahigh-Dose Mecobalamin for Amyotrophic Lateral Sclerosis in Japan |
| Eisai Co., Ltd. today announced that it has initiated preparation on a New Drug Application for ultrahigh-dose mecobalamin. more info >> |
|
| Friday, April 1, 2022 |
|
|
Eisai Announces Acquisition of Arteryex Shares (Making Arteryex a Subsidiary) to Strengthen and Rapidly Expand the Foundation of its Digital Solution Business |
| Eisai Co., Ltd. announced today that Eisai has acquired a majority of the shares issued by Arteryex Inc., a company that plans and develops software related to digital solutions such as provision of medical information platforms, through purchase of shares and subscription of a third-party allocation of common shares, and made it a subsidiary, as of March 31, 2022. more info >> |
|
| Monday, March 28, 2022 |
|
|
Eisai: Announcement About an Approval for Additional Indication of Jyseleca, JAK inhibitor |
| Gilead Sciences K.K., Eisai Co., Ltd. and EA Pharma Co., Ltd. announced that Gilead acquired an approval of additional indication of Jyseleca, Janus Kinase (JAK) inhibitor, for the treatment of patients with active moderate-to-severe ulcerative colitis in Japan. more info >> |
|
| Tuesday, March 22, 2022 |
|
|
Eisai: Latest Findings on Lecanemab Presented at AD/PD 2022 Annual Meeting |
| Eisai Co., Ltd. and Biogen Inc. announced today that the latest findings on lecanemab, an investigational anti-amyloid-beta (Abeta) protofibril antibody being developed for the treatment of early Alzheimer's disease (AD), were presented at the Abeta Targeted Therapies in AD 2 Symposium at the 2022 International Conference on Alzheimer's and Parkinson's Diseases (AD/PD) March 15-20 in Barcelona, Spain and virtually. more info >> |
|
| Tuesday, March 15, 2022 |
|
|
Eisai: Economic Arrangements of Amendment to Alzheimer's Disease Treatment Collaboration Agreement with Biogen |
| Eisai Co., Ltd. announced the following economic arrangements agreed in the amendment to Alzheimer's disease collaboration agreement with Biogen Inc. separately announced today. more info >> |
|
|
Biogen and Eisai Amend Collaboration Agreements on Alzheimer's Disease Treatments |
| Biogen Inc. and Eisai Co., Ltd. announced today that the companies have amended their existing collaboration agreement on aducanumab, which is commercialized in the United States as ADUHELM (aducanumab-avwa). more info >> |
|
| Friday, March 11, 2022 |
|
|
Eisai to Present New Lecanemab Data Exploring Distinct Mechanism of Action and Clinical Outcomes, Disease State (DSE) Symposium, and Other Pipeline Assets at the AD/PD 2022 Annual Meeting |
| Eisai Co., Ltd. announced today the company will present research from its robust Alzheimer's disease (AD) pipeline, including the latest findings on lecanemab, Eisai's investigational anti-amyloid beta (Abeta) protofibril antibody for the treatment of early AD at the AD/PD 2022 International Conference on Alzheimer's and Parkinson's Diseases (AD/PD) from March 15-20 in Barcelona, Spain and virtually. more info >> |
|
|
|
|
|
|
|
|
 |
| Latest Press Releases |
|
Kincora Appoints Kerry Stevenson and Michelle Borromeo to the Advisory Board
Oct 16, 2025 20:09 HKT/SGT
|
|
|
45th Electronics Fair and electronicAsia attract some 60,000 buyers
Oct 16, 2025 19:06 HKT/SGT
|
|
|
Radisson Expands Ongoing Step-Out Drill Program at O'Brien to 140,000 Metres
Oct 16, 2025 18:39 HKT/SGT
|
|
|
How DPC Dash-Domino's Pizza China Is Capturing China's Pizza Market
Oct 16, 2025 14:30 HKT/SGT
|
|
|
SERES Passes HKEX Listing Hearing - First 'A+H' Dual-Listed Premium NEV Maker Poised for Hong Kong Debut
Oct 16, 2025 14:28 HKT/SGT
|
|
|
Owkin Launches K Pro: The First Agentic AI Co-Pilot for Biopharma Powered by Biological Reasoning Models
Oct 16, 2025 13:00 HKT/SGT
|
|
|
Ceramics & Natural Stone Manufacturers Converge in Bangkok for ASEAN Ceramics & ASEAN Stone 2025
Oct 16, 2025 12:00 HKT/SGT
|
|
|
Discover the Secret to Your Best You Through Silica-Rich Hydration with Spritzer Natural Mineral Water
Oct 15, 2025 20:30 HKT/SGT
|
|
|
Mitsubishi Motors Wins Triple Honors at Good Design Award 2025 in Japan with the Delica Mini, Destinator and Delica Series
Oct 15, 2025 21:29 JST
|
|
|
Mitsubishi Motors at Japan Mobility Show 2025: World Premiere of Electrified Crossover SUV Concept
Oct 15, 2025 20:35 JST
|
|
|
Standard Chartered GBA Business Confidence Indices rise to multi-year high levels
Oct 15, 2025 19:08 HKT/SGT
|
|
|
Honda to Present World Premiere of ProZision(TM) Autonomous, at Equip Exposition 2025, Honda Battery-powered Autonomous Riding Lawn Mower
Oct 15, 2025 19:56 JST
|
|
|
Honda to Make Additional Investment in U.S.-based Helm.ai to Further Enhance Development of Next-generation AD/ADAS
Oct 15, 2025 19:25 JST
|
|
|
CITIC Telecom CPC Strengthens 'AI+ Cloud Network Security' Framework 'New MiiND for a Connected Future Beyond AI+ Security'
Oct 15, 2025 17:57 HKT/SGT
|
|
|
MHI Thermal Systems Wins 2025 GOOD DESIGN AWARD for Hyper Multi LXZ Series of Building-Use Multi-Split Air-Conditioners in Japan
Oct 15, 2025 18:50 JST
|
|
|
|
|
More Press release >> |
|
|
|
|
|
|
|
